naa a22 4500 510779948 CHVBK 20180411083243.0 cr unu---uuuuu 180411e20131001xx s 000 0 eng 10.1007/s11892-013-0412-x doi (NATIONALLICENCE)springer-10.1007/s11892-013-0412-x Bioengineered Sites for Islet Cell Transplantation [Elektronische Daten] [Sophie Vériter, Pierre Gianello, Denis Dufrane] Although islet transplantation has demonstrated its potential use in treating type 1 diabetes, this remains limited by the need for daily immunosuppression. Islet encapsulation was then proposed with a view to avoiding any immunosuppressive regimen and related side effects. In order to obtain a standard clinical procedure in terms of safety and reproducibility, two important factors have to be taken into account: the encapsulation design (which determines the graft volume) and the implantation site. Indeed, the implantation site should meet certain requirements: (1) its space must be large enough for the volume of transplanted tissues; (2) there must be proximity to abundant vascularization with a good oxygen supply; (3) there must be real-time access to physiologically representative blood glucose levels; (4) there must be easy access for implantation and the reversibility of the procedure (for safety); and finally, (5) the site should have minimal early inflammatory reaction and promote long-term survival. The aim of this article is to review possible preclinical/clinical implantation sites (in comparison with free islets) for encapsulated islet transplantation as a function of the encapsulation design: macro/microcapsules and conformal coating. Springer Science+Business Media New York, 2013 Islet cell transplantation nationallicence Encapsulation nationallicence Implantation site nationallicence Bioengineered sites nationallicence Vériter Sophie Unité de thérapie cellulaire endocrine, Centre de thérapie tissulaire et cellulaire, Cliniques universitaires Saint Luc, Tour Franklin +1 Sud, Avenue Mounier, 1200, Brussels, Belgium aut Gianello Pierre Pôle de Chirurgie Expérimentale et Transplantation, Institut de Recherche Expérimentale et Clinique, Secteur des Sciences de la Santé, Université catholique de Louvain, Tour Harvey, 5570,+4, Avenue Hippocrate, 1200, Brussels, Belgium aut Dufrane Denis Unité de thérapie cellulaire endocrine, Centre de thérapie tissulaire et cellulaire, Cliniques universitaires Saint Luc, Tour Franklin +1 Sud, Avenue Mounier, 1200, Brussels, Belgium aut Current Diabetes Reports Springer US; http://www.springer-ny.com 13/5(2013-10-01), 745-755 1534-4827 13:5<745 2013 13 11892 https://doi.org/10.1007/s11892-013-0412-x text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11892-013-0412-x text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Vériter Sophie Unité de thérapie cellulaire endocrine, Centre de thérapie tissulaire et cellulaire, Cliniques universitaires Saint Luc, Tour Franklin +1 Sud, Avenue Mounier, 1200, Brussels, Belgium aut NATIONALLICENCE 700 1- Gianello Pierre Pôle de Chirurgie Expérimentale et Transplantation, Institut de Recherche Expérimentale et Clinique, Secteur des Sciences de la Santé, Université catholique de Louvain, Tour Harvey, 5570,+4, Avenue Hippocrate, 1200, Brussels, Belgium aut NATIONALLICENCE 700 1- Dufrane Denis Unité de thérapie cellulaire endocrine, Centre de thérapie tissulaire et cellulaire, Cliniques universitaires Saint Luc, Tour Franklin +1 Sud, Avenue Mounier, 1200, Brussels, Belgium aut NATIONALLICENCE 773 0- Current Diabetes Reports Springer US; http://www.springer-ny.com 13/5(2013-10-01), 745-755 1534-4827 13:5<745 2013 13 11892 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer